Title: Heavy chain antibodies of camelid format as an alternative strategy to prevention, detection and control of allergic diseases

Biography:

Pramathadhip Paul is a Ph.D. senior research fellow at University of Calcutta, Department of Zoology, Immunology and Regenerative Medicine Research Laboratory, India. He has published seven papers in reputed journals.   He will try to convey his ideas with passion and enthusiasm which can help better drug discovery for the lung research.  As a young researcher he would work enthusiastically and refine their approach and it would be a great way to improve his performance for the drug discoveries.

Abstract

Antibodies are important therapeutic agents which are increasingly used in experimental research and medical applications. Antibody engineering, such as recombinant antibody fragments, have shown high specificity against various antigens.   Nanobodies or VHH are the special types of small proteins composed only of heavy chains from Camelids and represent a new generation of therapeutic immunecytical agents.  Most prominent advantages of VHH over conventional antibodies are their performance at high temperature up to 90ºC, stable folding, long CDR3 regions, and stability under harsh conditions. The purpose of our present research work is to explore, validate and characterize:  i) process (es), and ii) product (s) that could be used to develop diagnostic and therapeutic strategies for inflammatory and degenerative diseases, mainly systemic and tissue specific inflammation and extensive tissue damages and regressive loss of cellular structure. To this effect, novel nano-sized antibodies with a spectrum of convenient biophysical and biochemical properties have been used. Not only have we successfully generated proof-of-concept for the technology platform by simplifying the process of antibody generation in a complex mammalian system via introduction of simple yet powerful bioreactors such as bacteria and viruses, but also, the libraries of antigen specific camelid antibodies – anti α- amylase and anti-ovalbumin specific nanobody  provide a large number of clonal variations that may be modified and used to develop diagnostic kits for simple and non-invasive detection of presence of disease markers in body fluids for effective treatment of the patients.